Safety data sheet

1. Identification of the substance/preparation and of the company/undertaking

Revision: 08-02-2013/ FRSE
Replaces: 10-06-2011

Distributor:
Novo Nordisk A/S
External Environment
Novo Allé DK-2880 Bagsværd

Tel: +45 44 44 88 88  Fax: +45 44 49 05 55
Emergency telephone +45 44 42 00 00
Email address: compliance-team@novonordisk.com

2. Hazards identification

The product shall not be classified as hazardous according to (EC) No. 1272 / 2008, EU GHS/ CLP.

Additional information
No special risk if used in accordance with the instructions of the supplier.

3. Composition/information on ingredients

<table>
<thead>
<tr>
<th>REACH registration number</th>
<th>CAS No./Einecs no.</th>
<th>Substances</th>
<th>Classification/CLP-classification</th>
<th>w/w%</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td>204656-20-2</td>
<td>Solution for injection containing liraglutide [rDNA origin]</td>
<td>Not classified</td>
<td>-</td>
</tr>
</tbody>
</table>

*Please see section 16 for the full text of R-phrases and H-phrases.*

4. First aid measures

**Inhalation**
Remove to fresh air. If breathing is irregular, call a physician immediately.

**Ingestion**
When swallowed, seek medical attention and show the physician the package insert. Not expected to be active orally (hypoglycemia).

**Skin**
Wash with soap and water. Seek medical attention if irritation develops.

**Eyes**
Flush eyes with water for 15 minutes. If irritation develops, seek medical attention.

**Other information**
If in doubt, contact the doctor or emergency room. Always carry this manual or label.

5. Fire-fighting measures

The product is not readily flammable. Avoid breathing vapors and flue gases - seek fresh air.
Fire Fighting Extinguishing Media: In case of fire use foam, waterspray, dry chemical or CO2.
6. Accidental release measures

Use the same personal protective equipment as stated in section 8. Mop up spillage with a cloth. Dam spill and collect with sand or other absorbent material and place in suitable waste containers. For information on disposal please see item 13.

7. Handling and storage

Handling
See section 8 for information about precautions for use and personal protective equipment.

Storage
Victoza® should be stored in a refrigerator between 36 °F to 46 °F (2 °C to 8 °C). Do not freeze Victoza® and do not use Victoza® if it has been frozen. Store according to product instruction to prevent degradation.

8. Exposure controls/ personal protection

Precautions for use
Work under effective process ventilation (e.g. local exhaust ventilation). There must be access to running water and eye wash.

Respiratory protection
Not normally required.

Gloves and protective clothing
PVC gloves, nitril rubber or similar of greater protection are recommended for waste clean-up and manufacturing and packaging operations.

Eye protection
Clean-up, manufacturing and packaging operations may require safety glasses or goggles if there is a risk of splashing.

Occupational exposure limits
Contains no substances subject to reporting requirements.

9. Physical and chemical properties

Appearance: Clear, colorless solution
Odour: No particular

10. Stability and reactivity

No known incompatibilities. No known hazardous decomposition products.
11. Toxicological information

**Acute**

**Inhalation**
Not investigated. Inhalation of sprit mist containing protein may cause sensitization.

**Ingestion**
Absorption is not expected. Victoza causes a delay of gastric emptying, and thereby has the potential to impact the absorption of

**Skin contact**
May cause irritation by the active substance or any of the excipients.

**Eye contact**
May cause irritation. Avoid contact with the eyes.

**Risk of sensitization**
Hypersensitivity to the active substance or to any of the excipients.

**Long-term effects**

May cause damage to the reproductive system
Victoza® indicate no adverse effects of insulin on pregnancy and no malformative or feto/neonatal toxicity.

May cause genetic damage
Proteins are not expected to have any genotoxic potential, None of the excipients in Victoza® posses any genotoxic potential.

May cause irreversible damages
Repeated dose studies in animals did not identify any target organ toxicity.

12. Ecological information

Do not discharge large quantities of concentrated spills and residue into drains.

13. Disposal considerations

The product is not hazardous waste.
It is recommended that large quantities of waste and waste disposed of through the local receiving station with the following specifications.
Dispose of any cleanup materials and waste residue according to all applicable laws and regulations.

14. Transport information

The product is not covered by the rules for the transport of dangerous goods by road and sea according to ADR and IMDG.

15. Regulatory information

**Hazard designation:** It has been assessed that the product shall not be classified according to (EC) No. 1272 / 2008, EU GHS/ CLP.

**Contains**
Liraglutide

**Supplemental information**
None.

**Chemical safety assessment**
Chemical safety assessment has not been performed.
## 16. Other information

### Restrictions on use
None.

### Training requirement
No special training is necessary but a thorough knowledge of this safety data sheet is assumed.

### Sources used

### Other information
The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions.

Full text of the R-phrases that are stated in section 3.
No R-phrases.

Full text of the H-phrases that are stated in section 3.
No H-phrases.